In an effort to close the gap in neurological outcomes for underserved populations, a UTHealth Houston project funded with $2.9 million from the National Institutes of Health (NIH) will engage community partners to improve the design of clinical trials.
Semaglutide Cuts Liver Disease Severity in People With HIV
DENVER — Semaglutide (Ozempic) reduced the amount of liver fat by nearly a third in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD),
March 9, 2024